Supplementary Excel File 5 from Functional Synergies yet Distinct Modulators Affected by Genetic Alterations in Common Human Cancers
Supplementary File 11 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
Supplementary Excel File 9 from Functional Synergies yet Distinct Modulators Affected by Genetic Alterations in Common Human Cancers
Supplementary File 12 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
Supplementary File 2 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
Supplementary Excel File 7 from Functional Synergies yet Distinct Modulators Affected by Genetic Alterations in Common Human Cancers
Supplementary File 3 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
Supplementary Figure 2 from Functional Synergies yet Distinct Modulators Affected by Genetic Alterations in Common Human Cancers
Supplementary File 4 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
<p>List of the inhibitors tested for the ability to overcome CAF mediated resistance to lapatinib.</p>
Supplementary Tables 1-3 from Functional Synergies yet Distinct Modulators Affected by Genetic Alterations in Common Human Cancers
Supplementary Excel File 6 from Functional Synergies yet Distinct Modulators Affected by Genetic Alterations in Common Human Cancers
Supplementary Excel File 8 from Functional Synergies yet Distinct Modulators Affected by Genetic Alterations in Common Human Cancers
Supplementary File 6 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
Supplementary File 13 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
Supplementary File 7 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
Materials and Methods, Legends, Tables and Figures from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
<p>Associations between molecular features and clinical outcome. Patient outcome and changes in pSTAT3+, SMA+, Ki67+ cells and distance between Ki67+&SMA+ cells are indicated. Initial values from Day 0 where possible, otherwise Day 1. For continuous data, increase or decrease of at least 5% of initial value used as a threshold. Changes computed as Time0 - mean (Time 2,4,6 weeks). Outcome is percentage shrinkage of tumor at week 6.</p>
Supplementary File 8 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
Supplementary Figure Legends 1-5, Excel File Legends 1- from Functional Synergies yet Distinct Modulators Affected by Genetic Alterations in Common Human Cancers
Tatiana Nikolskaya合作论文数Vavilov Institute of General Genetics, Russian Academy of Sciences80
Kornelia Polyak合作论文数Dana-Farber Cancer Institute;Harvard Medical School38
Marina Bessarabova合作论文数29Zoltan Dezso合作论文数27Tatiana Serebryiskaya合作论文数20Andrej Bugrim合作论文数Computational Biology Genego Inc19
Victor E. Velculescu合作论文数Department of Genetic Medicine, School of Medicine, Johns Hopkins University;Delfi Diagnostics18Laura Mulvey合作论文数17Alex Ishkin合作论文数16Wendy Winckler合作论文数16Laura E Macconaill合作论文数Harvard Medical School, Dana-Farber Cancer Institute16Jun Yao合作论文数15Tatiana Serebriyskaya合作论文数15Pustovalova Olga合作论文数14
Weiwei Shi合作论文数Department of Electronic Engineering, The Chinese University of Hong Kong10
Tatiana V. Tatarinova合作论文数Division of Mathematics and Statistics, University of Glamorgan9Siân Jones合作论文数7
Weida Tong合作论文数Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration7
Russell Wolfinger合作论文数SAS;JMP Statistical Discovery LLC7
Kenneth W. Kinzler合作论文数Department of Oncology, School of Medicine, Johns Hopkins University;The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine7Rebecca J. Leary合作论文数7James Hartigan合作论文数6
Richard Gerald Brennan合作论文数Department of Biochemistry, Duke University School of Medicine6
Saraswati Sukumar合作论文数Department of Oncology, School of Medicine, Johns Hopkins University;Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University6
Cesare Furlanello合作论文数Centre for Scientific and Technological Research of Trento, Fondazione Bruno Kessler;LIGHT Center;OROBIX;HK3 Lab6
Richard S. Paules合作论文数National Institute of Environmental Health Sciences6
Sean Ekins合作论文数University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School;Collaborations Pharmaceuticals, Inc.6
Bert Vogelstein合作论文数Department of Molecular Biology and Genetics, Johns Hopkins School of Medicine6
Donald Williams Parsons合作论文数Department of Molecular and Human Genetics, Baylor College of Medicine6
Giovanni Parmigiani合作论文数Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University;Department of Data Science, Dana-Farber Cancer Institute6
Rachel Karchin合作论文数Department of Biomedical Engineering, Whiting School of Engineering, Johns Hopkins University;Department of Oncology, Johns Hopkins University;Institute for Computational Medicine, Johns Hopkins University6Svetlana Bureeva合作论文数Department of Biotechnology6
Pierre R. Bushel合作论文数BlueRock Therapeutics;Harvard T.H. Chan School of Public Health, Harvard University6Sergey Bruskin合作论文数6
Huixiao Hong合作论文数Division of Bioinformatics and Biostatistics, National Center for Toxicological Research6
Andrea L. Richardson合作论文数Department of Pathology, Johns Hopkins University6D Dosymbekov合作论文数5Eugene Kirillov合作论文数5
Hannah Carter合作论文数Department of Medicine, School of Medicine, University of California, San Diego5Nick Papadopoulos合作论文数5Zhenhua Wu合作论文数5
Leming Shi (石乐明)合作论文数Department of Anthropology and Human Genetics, School of Life Sciences, Fudan University5
Jimmy Lin合作论文数David R. Cheriton School of Computer Science, University of Waterloo5James C. Fuscoe合作论文数5
Reo Maruyama合作论文数5
X. Shirley Liu合作论文数GV20 Therapeutics5Zhenqiang Su合作论文数5Michail Shipitsin合作论文数5
